Microneedle Patch Delivery of PLCG1-siRNA Efficient Enhanced Temozolomide Therapy for Glioblastoma

Biomacromolecules. 2024 Feb 12;25(2):655-665. doi: 10.1021/acs.biomac.3c00846. Epub 2024 Jan 19.ABSTRACTThe blood-brain barrier (BBB) and drug resistance present challenges for chemotherapy of glioblastoma (GBM). A microneedle (MN) patch with excellent biocompatibility and biodegradability was designed to bypass the BBB and release temozolomide (TMZ) and PLCG1-siRNA directly into the tumor site for synergistic treatment of GBM. The codelivery of TMZ and PLCG1-siRNA enhanced DNA damage and apoptosis. The potential mechanism behind this enhancement is to knockdown of PLCG1 expression, which positively regulates the expression of signal transducer and activator of transcription 3 genes, thereby preventing DNA repair and enhancing the sensitivity of GBM to TMZ. The MN patch enables long-term sustainable drug release through in situ implantation and increases local drug concentrations in diseased areas, significantly extending mouse survival time compared to other drug treatment groups. MN drug delivery provides a platform for the combination treatment of GBM and other central nervous system diseases.PMID:38242535 | DOI:10.1021/acs.biomac.3c00846

Source: Biomacromolecules - January 19, 2024 Category: Biochemistry Authors: Zhipeng Yang Yanjie Liu Haoyuan Li Qisheng Tang Biao Yang Zhifeng Shi Ying Mao Source Type: research